Company / R&D Expense
BIOMERICA INC R&D Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.0M
FY2024
5-year range
$1.0M / $1.8M
FY2020-FY2024
Trend
-31.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 4 consecutive years, from $2M in FY2020 to $1M in FY2024.
Based on SEC 10-K filings.
$1M in FY2024 with a 5-year CAGR of -9.4%.
Declined from $2M to $1M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -17.4%
- 5-Year CAGR
- -9.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- BIOMERICA INC's r&d expense has declined for 4 consecutive years.
- 5-year CAGR of -9.4%, indicating a declining trend.
- In FY2024, r&d expense decreased 31.4% year-over-year.
- Peak r&d expense was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -6.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.0M | -31.4% |
| FY2023 | $1.5M | -5.9% |
| FY2022 | $1.6M | -12.6% |
| FY2021 | $1.8M | -17.4% |
| FY2020 | $2.2M | +30.7% |
| FY2019 | $1.7M | +0.0% |
| FY2018 | $1.7M | +20.1% |
| FY2017 | $1.4M | +23.7% |
| FY2016 | $1.1M | +44.9% |
As of FY2024 · SEC Form 10-K · Last checked Jun 22, 2026